On March 9, 2022 ArcticZymes Technologies ASA (OSE: AZT) reported the establishment of a new application development laboratory at ShareLab in Oslo (Press release, Biotec Pharmacon, MAR 9, 2022, View Source [SID1234609848]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ArcticZymes Technologies has signed an agreement with ShareLab AS to lease laboratory facilities at its premises in the Oslo Science Park. These facilities will support application development activities to demonstrate the utility of the Company´s enzymes in customer relevant workflows and technologies. This is an essential part of the innovation process and strengthens the commercial value proposition of the Company´s product offerings.
ShareLab is a service platform provider of laboratory and office facilities to biotechnology companies. It conveniently provides the necessary amenities and shared core equipment suited to ArcticZymes´ requirements which means minimal capital investments to get started. Furthermore, ShareLab´s location in the Oslo Science Park is central to the Norwegian biotechnology industry and life science research.
The Oslo location will allow access to a broad talent pool of commercially-experienced application scientists. Also, as the Company continues to grow it has strategic relevance to have part of ArcticZymes located at the heart of the Norwegian biotech industry.
Dr. Darren Ellis has been hired to lead the activities at ShareLab and is currently recruiting two application scientists. Dr. Ellis brings over 20 years of industrial R&D experience (from Solexa (now Illumina) and Thermo Fisher Scientific) in leading and developing molecular research and In Vitro Diagnostic (IVD) applications, technologies, and products. Furthermore, he has global expertise in Business-to-Business (B2B) application development, successfully helping commercial partners/customers to bring their technologies and product developments to market.